PADI4 and metabolic dysfunction-associated steatohepatitis: Increased NET levels have been observed in the serum of both nonalcoholic steatohepatitis (NASH) [245] and HCC patients [195], suggesting that PAD4 may be involved in the progression of hepatitis to liver cancer and contribute to the malignant transformation of liver disease into HCC.